Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop

Gene Therapy

Volumn 11, Issue 18, 2004, Pages 1399-1407

  Woraratanadharm, J ^a   Rubinchik, S ^a   Yu, H ^a   Fan, F ^a   Morrow, S M ^a   Dong, J Y ^a,b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b GenPhar Inc   (United States)

^c NONE   (United States)

Author keywords

Adenovirus; ARR2PB promoter; Positive feedback loop; Prostate cancer; Tet responsive element (TRE)

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; CELL PROTEIN; GREEN FLUORESCENT PROTEIN; TETRACYCLINE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL SPECIFICITY; CONTROLLED STUDY; ESSENTIAL GENE; FEEDBACK SYSTEM; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ENHANCEMENT; GENETIC REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE CANCER; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; CELL LINE, TUMOR; FEEDBACK, BIOCHEMICAL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MALE; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATIC NEOPLASMS; RESPONSE ELEMENTS; TRANSFECTION;

ADENOVIRIDAE;

EID: 4644262107     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302307     Document Type: Article

References (51)

1. Cancer Facts & Figures 2003. Compiled by the American Cancer Society, 2003.
2. Pound CR et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406.
3. Meuleman EJ, Mulders PF. Erectile function after radical prostatectomy: a review. Eur Urol 2003; 43: 95-101; (discussion 101-102).
4. Hara I et al. Comparison of quality of life following laparoscopic and open prostatectomy for prostate cancer. J Urol 2003; 169: 2045-2048.
5. Dahm P et al. A longitudinal assessment of bowel related symptoms and fecal incontinence following radical perineal prostatectomy. J Urol 2003; 169: 2220-2224.
6. Kirschner-Hermanns R, Jakse G. Quality of life following radical prostatectomy. Crit Rev Oncol Hematol 2002; 43: 141-151.
7. Klein EA et al. Locally advanced prostate cancer. Curr Treat Options Oncol 2001; 2: 403-411.
8. Doehn C, Jocham D. Technology evaluation: CV-787, Calydon Inc. Curr Opin Mol Ther 2001; 3: 204-210.
9. Kubo H et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14: 227-241.
10. Shirakawa T et al. Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol Urol 2000; 4: 73-82.
11. Snoek R et al. Differential transactivation by the androgen receptor in prostate cancer cells. Prostate 1998; 36: 256-263.
12. Kasper S et al. Selective activation of the probasin androgen-responsive region by steroid hormones. J Mol Endocrinol 1999; 22: 313-325.
13. Zhang J et al. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 141: 4698-4710.
14. Wu X et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001; 101: 61-69.
15. Andriani F et al. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 2001; 93: 1314-1324.
16. Rubinchik S et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther 2001; 4: 416-426.
17. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
18. Furth PA et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 1994; 91: 9302-9306.
19. Kistner A et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 1996; 93: 10933-10938.
20. Howe JR et al. The responsiveness of a tetracycline-sensitive expression system differs in different cell lines. J Biol Chem 1995; 270: 14168-14174.
21. Rubinchik S et al. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters. Gene Therapy 2001; 8: 247-253.
22. Rubinchik S, Norris JS, Dong JY. Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol 2002; 346: 529-547.
23. Rubinchik S et al. Improving the transcriptional regulation of genes delivered by adenovirus vectors. Methods in Molecular Medicine 2003; 76: 167-199.
24. Rubinchik S et al. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Therapy 2000; 7: 875-885.
25. Kanai F. Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector. Mol Biotechnol 2001; 18: 243-250.
26. Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 2001; 53: 135-154.
27. Hyer ML et al. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2000; 2: 348-358.
28. Rubinchik S et al. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther 2003; 10: 814-822.
29. Seol JY et al. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther 2003; 10: 540-548.
30. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9: 164-172.
31. Komatsu K et al. Cre-loxP-mediated bax gene activation reduces growth rate and increases sensitivity to chemotherapeutic agents in human gastric cancer cells. Cancer Gene Ther 2000; 7: 885-892.
32. Lee A et al. Bax expressed from a herpes viral vector enhances the efficacy of N,N′-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model. Cancer Gene Ther 2000; 7: 1113-1119.
33. Shinoura N et al. Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther 2000; 7: 739-748.
34. Fillat C et al. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3: 13-26.
35. Nishihara E et al. Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro. Anticancer Res 1998; 18: 1521-1525.
36. Yazawa K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg 2002; 26: 783-789.
37. Kirn D et al. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002; 8: S68-S73.
38. van Beusechem VW et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Therapy 2003; 10: 1982-1991.
39. Yamamoto M et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003; 125: 1203-1218.
40. Wildner O. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr Opin Mol Ther 2003; 5: 351-361.
41. Volk AL et al. Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther 2003; 2: 511-515.
42. Buskens CJ et al. A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens. Ann Surg 2003; 238: 815-824; (discussion 825-816).
43. Belousova N et al. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002; 76: 8621-8631.
44. Wesseling JG et al. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Therapy 2001; 8: 969-976.
45. Heideman DA et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 2001; 8: 342-351.
46. Vigne E et al. Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Therapy 2003; 10: 153-162.
47. Nakamura T, Sato K, Hamada H. Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J Virol 2003; 77: 2512-2521.
48. Jongmans W et al. Targeting of adenovirus to human renal cell carcinoma cells. Urology 2003; 62: 559-565.
49. Nettelbeck DM et al. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 2004; 108: 136-145.
50. Henning P et al. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum Gene Ther 2002; 13: 1427-1439.
51. Kashentseva EA et al. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 2002; 62: 609-616.